MX2020014296A - Variantes de interleucina-2 y sus métodos de uso. - Google Patents

Variantes de interleucina-2 y sus métodos de uso.

Info

Publication number
MX2020014296A
MX2020014296A MX2020014296A MX2020014296A MX2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A MX 2020014296 A MX2020014296 A MX 2020014296A
Authority
MX
Mexico
Prior art keywords
cells
polypeptides
relates
present
pharmaceutical compositions
Prior art date
Application number
MX2020014296A
Other languages
English (en)
Inventor
Yue- Sheng LI
Lingyun Rui
Jing Xu
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Publication of MX2020014296A publication Critical patent/MX2020014296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a polipéptidos que comparten la secuencia primaria con IL-2 humana, excepto por varios aminoácidos que se han mutado. Un panel de variantes de IL-2 comprende mutaciones con una capacidad de elaboración impresionante que promueve preferentemente la proliferación, supervivencia, activación y/o función de las células T reguladoras inmunosupresoras (Treg: CD4+CD25+F0xP3+) sobre las células T efectoras y las células NK. También incluye los usos terapéuticos de dicho agente selectivo de IL-2, utilizado solo o en combinación con agentes inmunomoduladores o anticuerpos, proteínas o péptidos dirigidos al tejido de la enfermedad para tratar la deficiencia de células Treg, diversos trastornos autoinmunes e inflamatorios, trasplante de órganos y la enfermedad de injerto contra huésped. En otro aspecto, la presente invención se refiere a composiciones farmacéuticas que comprenden los polipéptidos descritos. Finalmente, la presente invención se refiere al uso terapéutico de los polipéptidos y composiciones farmacéuticas descritos debido a su efecto modulador selectivo del sistema inmune sobre enfermedades tal como trastornos autoinmunes e inflamatorios.
MX2020014296A 2018-06-22 2019-06-20 Variantes de interleucina-2 y sus métodos de uso. MX2020014296A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689055P 2018-06-22 2018-06-22
US201862755016P 2018-11-02 2018-11-02
PCT/US2019/038248 WO2019246404A1 (en) 2018-06-22 2019-06-20 Interleukin-2 variants and methods of uses thereof

Publications (1)

Publication Number Publication Date
MX2020014296A true MX2020014296A (es) 2021-08-05

Family

ID=68984319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014296A MX2020014296A (es) 2018-06-22 2019-06-20 Variantes de interleucina-2 y sus métodos de uso.

Country Status (9)

Country Link
US (2) US20210269497A1 (es)
EP (1) EP3810185A4 (es)
JP (1) JP2021528105A (es)
KR (1) KR20210033995A (es)
CN (1) CN112638406A (es)
AU (1) AU2019288496A1 (es)
CA (1) CA3102829A1 (es)
MX (1) MX2020014296A (es)
WO (1) WO2019246404A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252418A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants for the treatment of cancer
CN114728040A (zh) * 2019-06-14 2022-07-08 科优基因公司 新型白介素-2变体及其双功能融合分子
AU2021206449A1 (en) * 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090674A4 (en) * 2020-01-14 2024-01-24 Synthekine Inc METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS
CN115066253A (zh) * 2020-01-14 2022-09-16 辛德凯因股份有限公司 Il2突变蛋白
CA3175717A1 (en) * 2020-03-19 2021-09-23 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 mutant and use thereof
KR102545250B1 (ko) * 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
KR20230035076A (ko) * 2020-07-02 2023-03-10 인히브릭스, 인크. 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도
US20230303680A1 (en) * 2020-08-18 2023-09-28 Universität Zürich A cd25-biased anti-il-2 antibody
KR20230124030A (ko) * 2020-12-23 2023-08-24 머크 샤프 앤드 돔 엘엘씨 자가면역 및 염증성 질환을 치료하기 위한 il-2 뮤테인
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
RU2312677C9 (ru) * 2001-12-04 2008-03-27 Мерк Патент Гмбх Иммуноцитокины с модулированной селективностью
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US20100098730A1 (en) * 2008-10-14 2010-04-22 Lowman Henry B Immunoglobulin variants and uses thereof
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
AU2017281469B2 (en) * 2016-06-22 2023-08-31 David Klatzmann Genetically modified T lymphocytes
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
JP2021528105A (ja) 2021-10-21
EP3810185A4 (en) 2022-03-23
CA3102829A1 (en) 2019-12-26
EP3810185A1 (en) 2021-04-28
US20240059751A1 (en) 2024-02-22
KR20210033995A (ko) 2021-03-29
US20210269497A1 (en) 2021-09-02
AU2019288496A1 (en) 2021-01-14
WO2019246404A1 (en) 2019-12-26
CN112638406A (zh) 2021-04-09

Similar Documents

Publication Publication Date Title
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
NZ761434A (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
PH12020500648A1 (en) Il-15 variants and uses thereof
WO2020252421A3 (en) Novel interleukin-2 variants and bifunctional fusion molecules thereof
EA201390681A1 (ru) Производные полипептиды il-2 с агонистической активностью для лечения рака и хронических инфекций
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA202091754A1 (ru) Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
Kim et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
MX2023005346A (es) Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8.
Pang et al. Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EA202190572A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы
MX2019007906A (es) Composicion vacunal que comprende un mutante de la interleucina-15 humana.
EA202190169A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по b*07 пептидами и комбинациями пептидов и относящиеся к ней способы